Literature DB >> 12709356

Genetic screen for monitoring hepatitis C virus NS3 serine protease activity.

Miguel Angel Martinez1, Bonaventura Clotet.   

Abstract

We have developed a genetic system to monitor the activity of the hepatitis C virus (HCV) NS3 serine protease. This genetic system is based on the bacteriophage lambda regulatory circuit where the viral repressor cI is specifically cleaved to initiate the switch from lysogeny to lytic infection. An HCV protease-specific target, NS5A-5B, was inserted into the lambda phage cI repressor. The target specificity of the HCV NS5A-5B repressor was evaluated by coexpression of this repressor with a beta-galactosidase (betagal)-HCV NS3(2-181)/4(21-34) protease construct. Upon infection of Escherichia coli cells containing the two plasmids encoding the cI.HCV5AB-cro and the betagal-HCV NS3(2-181)/4(21-34) protease constructs, lambda phage replicated up to 8,000-fold more efficiently than in cells that did not express the HCV NS3(2-181)/4(21-34) protease. This simple, rapid, and highly specific assay can be used to monitor the activity of the HCV NS3 serine protease, and it has the potential to be used for screening specific inhibitors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12709356      PMCID: PMC153332          DOI: 10.1128/AAC.47.5.1760-1765.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  In vivo determination of substrate specificity of hepatitis C virus NS3 protease: genetic assay for site-specific proteolysis.

Authors:  S Y Kim; K W Park; Y J Lee; S H Back; J H Goo; O K Park; S K Jang; W J Park
Journal:  Anal Biochem       Date:  2000-08-15       Impact factor: 3.365

2.  Catalytic efficiency and phenotype of HIV-1 proteases encoding single critical resistance substitutions.

Authors:  Marta Cabana; Guerau Fernàndez; Mariona Parera; Bonaventura Clotet; Miguel Angel Martínez
Journal:  Virology       Date:  2002-08-15       Impact factor: 3.616

Review 3.  Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel.

Authors:  C C Carpenter; D A Cooper; M A Fischl; J M Gatell; B G Gazzard; S M Hammer; M S Hirsch; D M Jacobsen; D A Katzenstein; J S Montaner; D D Richman; M S Saag; M Schechter; R T Schooley; M A Thompson; S Vella; P G Yeni; P A Volberding
Journal:  JAMA       Date:  2000-01-19       Impact factor: 56.272

4.  A personal account of the role of peptide research in drug discovery: the case of hepatitis C.

Authors:  A Pessi
Journal:  J Pept Sci       Date:  2001-01       Impact factor: 1.905

5.  Rapid genetic selection of inhibitor-resistant protease mutants: clinically relevant and novel mutants of the HIV protease.

Authors:  H J Sices; M D Leusink; A Pacheco; T M Kristie
Journal:  AIDS Res Hum Retroviruses       Date:  2001-09-01       Impact factor: 2.205

6.  Reconstitution of hepatitis C virus protease activities in yeast.

Authors:  P Mak; O Palant; P Labonté; S Plotch
Journal:  FEBS Lett       Date:  2001-08-10       Impact factor: 4.124

7.  NS3 is a serine protease required for processing of hepatitis C virus polyprotein.

Authors:  L Tomei; C Failla; E Santolini; R De Francesco; N La Monica
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

8.  Genetic organization and diversity of the hepatitis C virus.

Authors:  Q L Choo; K H Richman; J H Han; K Berger; C Lee; C Dong; C Gallegos; D Coit; R Medina-Selby; P J Barr
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

9.  Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.

Authors:  V Lohmann; F Körner; J Koch; U Herian; L Theilmann; R Bartenschlager
Journal:  Science       Date:  1999-07-02       Impact factor: 47.728

Review 10.  Recent advances in the molecular biology of hepatitis C virus.

Authors:  S Rosenberg
Journal:  J Mol Biol       Date:  2001-10-26       Impact factor: 5.469

View more
  10 in total

1.  Sequence homology required by human immunodeficiency virus type 1 to escape from short interfering RNAs.

Authors:  Rosario Sabariegos; Mireia Giménez-Barcons; Natalia Tàpia; Bonaventura Clotet; Miguel Angel Martínez
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

2.  Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay.

Authors:  Donald R O'Boyle; Peter T Nower; Julie A Lemm; Lourdes Valera; Jin-Hua Sun; Karen Rigat; Richard Colonno; Min Gao
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

3.  Genetic screen for monitoring severe acute respiratory syndrome coronavirus 3C-like protease.

Authors:  Mariona Parera; Bonaventura Clotet; Miguel Angel Martinez
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

4.  Fitness landscape of human immunodeficiency virus type 1 protease quasispecies.

Authors:  Guerau Fernàndez; Bonaventura Clotet; Miguel Angel Martínez
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

5.  Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patients.

Authors:  Ester Aparicio; Sandra Franco; Mariona Parera; Cristina Andrés; Cristina Tural; Bonaventura Clotet; Miguel Angel Martínez
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

6.  Fluorescence resonance energy transfer-based assay for characterization of hepatitis C virus NS3-4A protease activity in live cells.

Authors:  Rosario Sabariegos; Fernando Picazo; Beatriz Domingo; Sandra Franco; Miguel-Angel Martinez; Juan Llopis
Journal:  Antimicrob Agents Chemother       Date:  2008-12-08       Impact factor: 5.191

7.  Canine hepacivirus NS3 serine protease can cleave the human adaptor proteins MAVS and TRIF.

Authors:  Mariona Parera; Gloria Martrus; Sandra Franco; Bonaventura Clotet; Miguel Angel Martinez
Journal:  PLoS One       Date:  2012-08-01       Impact factor: 3.240

8.  Induction of cell-mediated immune responses in mice by DNA vaccines that express hepatitis C virus NS3 mutants lacking serine protease and NTPase/RNA helicase activities.

Authors:  Suratno Lulut Ratnoglik; Da-Peng Jiang; Chie Aoki; Pratiwi Sudarmono; Ikuo Shoji; Lin Deng; Hak Hotta
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

9.  HIV-1 protease catalytic efficiency effects caused by random single amino acid substitutions.

Authors:  Mariona Parera; Guerau Fernàndez; Bonaventura Clotet; Miguel Angel Martínez
Journal:  Mol Biol Evol       Date:  2006-11-07       Impact factor: 16.240

10.  Insertional protein engineering for analytical molecular sensing.

Authors:  Rosa María Ferraz; Andrea Vera; Anna Arís; Antonio Villaverde
Journal:  Microb Cell Fact       Date:  2006-04-03       Impact factor: 5.328

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.